We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
Read MoreHide Full Article
Key Takeaways
ADMA shares surged 20.9% after better-than-expected Q3 results, outperforming the declining industry.
Asceniv revenues jumped 31% year over year, driven by physician adoption and higher patient utilization.
ADMA raised minimum 2026 adjusted net income and EBITDA outlooks, despite Bivigam sales decline.
ADMA Biologics’ (ADMA - Free Report) shares have gained 20.9% over the past week against the industry’s decline of 0.4%.
The stock rallied after the company reported better-than-expected results for the third quarter on Nov. 4, 2026.
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Year to date, shares of the company have gained 29.5% compared with the industry’s growth of 6.3%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame.
ADMA Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Robust demand for lead drug Asceniv maintains momentum for the company amid declining Bivigam sales.
ADMA reiterated its full-year 2026 revenue expectation of at least $530 million. The outlook reflects continued Asceniv momentum alongside conservative assumptions about competition in the standard immune globulin market.
The company raised its minimum adjusted net income outlook to $180 million and minimum adjusted EBITDA outlook to $275 million. In the second quarter, management had projected adjusted net income of $170-$200 million and adjusted EBITDA of $265-$300 million.
Against this backdrop, a closer examination of ADMA’s key strengths and potential challenges is warranted to better assess the stock’s investment appeal.
Asceniv Fuels ADMA’s Top-Line Growth
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies.
Asceniv remained the key contributor to ADMA’s revenue performance in the third quarter, while the company’s other product lines trended in the opposite direction.
Asceniv’s revenues surged 31% year over year and 21% sequentially, driven by increased physician adoption, higher new patient starts and stronger end-user utilization. Favorable demand trends have continued into the fourth quarter, underscoring the product’s sustained growth momentum and substantial untapped market opportunity.
ADMA plans to present an analysis of 127 medically complex patients with primary immunodeficiency treated with Asceniv at the American College of Allergy, Asthma and Immunology (“ACAAI”) annual conference shortly. Most patients had previously received other immune globulin therapies.
The analysis showed statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, and the use of oral antibiotics and corticosteroids following the initiation of Asceniv treatment. These findings support Asceniv’s positioning as a treatment option for later-line, refractory and medically complex PI patients.
Bivigam Sales Decline But Show Signs of Stabilization
Bivigam generated third-quarter revenues of $15.4 million, down from $19.4 million in the second quarter, reflecting continued competitive pricing and channel inventory pressures in the standard immunoglobulin (IG) market. Sales declined 47.1% in the first nine months of 2026.
Nonetheless, underlying end-user utilization showed encouraging signs of stabilization heading into the fourth quarter. ADMA continues to prioritize disciplined commercial execution rather than matching aggressive competitor discounting and rebate practices.
ADMA’s Valuation & Estimates
Going by the price/sales ratio, ADMA’s shares currently trade at 4.56x forward sales, higher than its mean of 3.78x and the industry’s 2x.
Image Source: Zacks Investment Research
Estimate Movement
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved north to 82 cents from 78 cents in the past seven days, while that for 2027 EPS has inched up to 86 cents from 85 cents in the same time frame.
Image Source: Zacks Investment Research
Stay Invested in ADMA Stock for Now
ADMA Biologics, which competes with Takeda (TAK - Free Report) and Grifols (GRFS - Free Report) in the U.S. market for plasma-derived products, has effectively navigated competitive pressures in the immunoglobulin (IG) market throughout 2026.
Strong growth in Asceniv sales, expanding physician adoption and encouraging real-world clinical evidence support its revenue growth prospects.
The company also raised its minimum adjusted net income and EBITDA outlook for 2026, while positive earnings estimate revisions reflect improving analyst sentiment.
However, continued weakness in Bivigam sales, competitive pricing and channel inventory pressures in the standard IG market remain concerns. Moreover, the stock’s sharp recent rally and premium valuation relative to its historical average and industry limit the upside from current levels.
While ADMA’s growth prospects remain encouraging, these risks warrant a balanced approach. Existing investors can continue to hold the stock, while new investors may wait for a better entry point.
View the Zacks #1 Rank List
Image: Bigstock
ADMA Surges 20.9% Post Q3 Earnings: Buy, Sell or Hold the Stock?
Key Takeaways
ADMA Biologics’ (ADMA - Free Report) shares have gained 20.9% over the past week against the industry’s decline of 0.4%.
The stock rallied after the company reported better-than-expected results for the third quarter on Nov. 4, 2026.
ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases.
The company’s top line currently comprises sales of three FDA-approved products — Bivigam (an Intravenous Immune Globulin [“IVIG”] product to treat primary humoral immunodeficiency), Asceniv (to treat primary immunodeficiency disease or PIDD) and Nabi-HB (to treat and provide enhanced immunity against the hepatitis B virus).
Year to date, shares of the company have gained 29.5% compared with the industry’s growth of 6.3%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame.
ADMA Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Robust demand for lead drug Asceniv maintains momentum for the company amid declining Bivigam sales.
ADMA reiterated its full-year 2026 revenue expectation of at least $530 million. The outlook reflects continued Asceniv momentum alongside conservative assumptions about competition in the standard immune globulin market.
The company raised its minimum adjusted net income outlook to $180 million and minimum adjusted EBITDA outlook to $275 million. In the second quarter, management had projected adjusted net income of $170-$200 million and adjusted EBITDA of $265-$300 million.
Against this backdrop, a closer examination of ADMA’s key strengths and potential challenges is warranted to better assess the stock’s investment appeal.
Asceniv Fuels ADMA’s Top-Line Growth
Asceniv, its lead product, is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies.
Asceniv remained the key contributor to ADMA’s revenue performance in the third quarter, while the company’s other product lines trended in the opposite direction.
Asceniv’s revenues surged 31% year over year and 21% sequentially, driven by increased physician adoption, higher new patient starts and stronger end-user utilization. Favorable demand trends have continued into the fourth quarter, underscoring the product’s sustained growth momentum and substantial untapped market opportunity.
ADMA plans to present an analysis of 127 medically complex patients with primary immunodeficiency treated with Asceniv at the American College of Allergy, Asthma and Immunology (“ACAAI”) annual conference shortly. Most patients had previously received other immune globulin therapies.
The analysis showed statistically significant reductions in infection-related hospitalizations, outpatient healthcare utilization, and the use of oral antibiotics and corticosteroids following the initiation of Asceniv treatment. These findings support Asceniv’s positioning as a treatment option for later-line, refractory and medically complex PI patients.
Bivigam Sales Decline But Show Signs of Stabilization
Bivigam generated third-quarter revenues of $15.4 million, down from $19.4 million in the second quarter, reflecting continued competitive pricing and channel inventory pressures in the standard immunoglobulin (IG) market. Sales declined 47.1% in the first nine months of 2026.
Nonetheless, underlying end-user utilization showed encouraging signs of stabilization heading into the fourth quarter. ADMA continues to prioritize disciplined commercial execution rather than matching aggressive competitor discounting and rebate practices.
ADMA’s Valuation & Estimates
Going by the price/sales ratio, ADMA’s shares currently trade at 4.56x forward sales, higher than its mean of 3.78x and the industry’s 2x.
Image Source: Zacks Investment Research
Estimate Movement
The Zacks Consensus Estimate for ADMA’s 2026 earnings per share has moved north to 82 cents from 78 cents in the past seven days, while that for 2027 EPS has inched up to 86 cents from 85 cents in the same time frame.
Image Source: Zacks Investment Research
Stay Invested in ADMA Stock for Now
ADMA Biologics, which competes with Takeda (TAK - Free Report) and Grifols (GRFS - Free Report) in the U.S. market for plasma-derived products, has effectively navigated competitive pressures in the immunoglobulin (IG) market throughout 2026.
Strong growth in Asceniv sales, expanding physician adoption and encouraging real-world clinical evidence support its revenue growth prospects.
The company also raised its minimum adjusted net income and EBITDA outlook for 2026, while positive earnings estimate revisions reflect improving analyst sentiment.
However, continued weakness in Bivigam sales, competitive pricing and channel inventory pressures in the standard IG market remain concerns. Moreover, the stock’s sharp recent rally and premium valuation relative to its historical average and industry limit the upside from current levels.
While ADMA’s growth prospects remain encouraging, these risks warrant a balanced approach. Existing investors can continue to hold the stock, while new investors may wait for a better entry point.
ADMA currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.